Search

Your search keyword '"Hilbrands, Luuk B."' showing total 733 results
Start Over Author "Hilbrands, Luuk B."
733 results on '"Hilbrands, Luuk B."'

1. Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Kho, Marcia M. L., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, Reinders, Marlies E. J., Baan, Carla C., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

2. Trained immunity suppression determines kidney allograft survival

Author

Jonkman, Inge, Jacobs, Maaike M.E., Negishi, Yutaka, Yanginlar, Cansu, Martens, Joost H.A., Baltissen, Marijke, Vermeulen, Michiel, van den Hoogen, Martijn W.F., Baas, Marije, van der Vlag, Johan, Fayad, Zahi A., Teunissen, Abraham J.P., Madsen, Joren C., Ochando, Jordi, Joosten, Leo A.B., Netea, Mihai G., Mulder, Willem J.M., Mhlanga, Musa M., Hilbrands, Luuk B., Rother, Nils, and Duivenvoorden, Raphaël

Published
2024
Full Text
View/download PDF

3. Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling

Author

Jacobs, Maaike M.E., Maas, Rianne J.F., Jonkman, Inge, Negishi, Yutaka, Tielemans Zamora, Willem, Yanginlar, Cansu, van Heck, Julia, Matzaraki, Vasiliki, Martens, Joost H.A., Baltissen, Marijke, Vermeulen, Michiel, Morla-Folch, Judit, Ranzenigo, Anna, Wang, William, Umali, Martin, Ochando, Jordi, van der Vlag, Johan, Hilbrands, Luuk B., Joosten, Leo A.B., Netea, Mihai G., Mulder, Willem J.M., van Leent, Mandy M.T., Mhlanga, Musa M., Teunissen, Abraham J.P., Rother, Nils, and Duivenvoorden, Raphaël

Published
2024
Full Text
View/download PDF

5. Association of obesity with 3-month mortality in kidney failure patients with COVID-19.

Author

Tantisattamo, Ekamol, Imhof, Celine, Jager, Kitty J, Hilbrands, Luuk B, Guidotti, Rebecca, Islam, Mahmud, Katicic, Dajana, Konings, Constantijn, Molenaar, Femke M, Nistor, Ionut, Noordzij, Marlies, Rodríguez Ferrero, María Luisa, Verhoeven, Martine AM, de Vries, Aiko PJ, Kalantar-Zadeh, Kamyar, Gansevoort, Ron T, Vart, Priya, and ERACODA collaborators

Subjects
ERACODA collaborators, COVID-19, kidney failure, mortality, obesity paradox, reverse epidemiology, Kidney Disease, Obesity, Nutrition, Prevention, Renal and urogenital, Good Health and Well Being
Abstract

BackgroundIn the general population with coronavirus disease 2019 (COVID-19), obesity is associated with an increased risk of mortality. Given the typically observed obesity paradox among patients on kidney function replacement therapy (KFRT), especially dialysis patients, we examined the association of obesity with mortality among dialysis patients or living with a kidney transplant with COVID-19.MethodsData from the European Renal Association COVID-19 Database (ERACODA) were used. KFRT patients diagnosed with COVID-19 between 1 February 2020 and 31 January 2021 were included. The association of Quetelet's body mass index (BMI) (kg/m2), divided into:

Published
2022

6. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, Geers, Daryl, Bogers, Susanne, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M. L., Reinders, Marlies E. J., de Vries, Rory D., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

7. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

Author

Hemmelder, Marc H, Noordzij, Marlies, Vart, Priya, Hilbrands, Luuk B, Jager, Kitty J, Abrahams, Alferso C, Arroyo, David, Battaglia, Yuri, Ekart, Robert, Mallamaci, Francesca, Malloney, Sharon-Rose, Oliveira, Joao, Rydzewski, Andrzej, Sridharan, Sivakumar, Vogt, Liffert, Duivenvoorden, Raphaël, Gansevoort, Ron T, Franssen, Casper FM, van der Net, Jeroen B, Essig, Marie, du Buf-Vereijken, Peggy WG, van Ginneken, Betty, Maas, Nanda, van Jaarsveld, Brigit C, Bemelman, Frederike J, Klingenberg-Salahova, Farah, Heenan-Vos, Frederiek, Vervloet, Marc G, Nurmohamed, Azam, Abramowicz, Daniel, Verhofstede, Sabine, Maoujoud, Omar, Malfait, Thomas, Fialova, Jana, Melilli, Edoardo, Favà, Alexandre, Cruzado, Josep M, Perez, Nuria Montero, Lips, Joy, Krepel, Harmen, Adilovic, Harun, Hengst, Maaike, Konings, Constantijn JAM, Braconnier, Philippe, Weis, Daniel, Gellert, Ryszard, Alferes, Daniela G, Radulescu, Daniela, Zakharova, Elena V, Ambuehl, Patrice Max, Guidotti, Rebecca, Walker, Andrea, Lepeytre, Fanny, Rabaté, Clémentine, Rostoker, Guy, Marques, Sofia, Azasevac, Tijana, Majstorovic, Gordana Strazmester, Katicic, Dajana, Dam, Marc ten, Krüger, Thilo, Brzosko, Szymon, Liakopoulos, Vassilios, Zanen, Adriaan L, Logtenberg, Susan JJ, Fricke, Lutz, Kuryata, Olexandr, Slebe, Jeroen JP, ElHafeez, Samar Abd, Kemlin, Delphine, van de Wetering, Jacqueline, Reinders, Marlies EJ, Hesselink, Dennis A, van Gestel, J Kal-, Eiselt, Jaromir, Kielberger, Lukas, El-Wakil, Hala S, Verhoeven, Martine AM, Logan, Ian, Canal, Cristina, Facundo, Carme, Ramos, Ana M, Debska-Slizien, Alicja, Veldhuizen, Nicoline MH, Tigka, Eirini, Konsta, Maria Anna Polyzou, Panagoutsos, Stylianos, Postorino, Adele, Cambareri, Francesco, Matceac, Irina, Nistor, Ionut, Covic, Adrian, Groeneveld, JHM, Jousma, Jolanda, van Buren, Marjolijn, Diekmann, Fritz, Oppenheimer, Federico, Blasco, Miquel, Pereira, Tiago Assis, and dos Santos, Augusto Cesar Soares

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, Patient Safety, Clinical Research, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Aged, Aged, 80 and over, COVID-19, COVID-19 Testing, Female, Humans, Intensive Care Units, Male, Middle Aged, Outcome Assessment, Health Care, Renal Dialysis, SARS-CoV-2, ERACODA Collaborators, dialysis, functional health status, mental health status, survival, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCoronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis.MethodsWe analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression.ResultsIn 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8-6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome.ConclusionsMortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

Published
2022

8. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19

Author

Duivenvoorden, Raphaël, Vart, Priya, Noordzij, Marlies, dos Santos, Augusto C Soares, Zulkarnaev, Alex B, Franssen, Casper FM, Kuypers, Dirk, Demir, Erol, Rahimzadeh, Hormat, Kerschbaum, Julia, Jager, Kitty J, Turkmen, Kultigin, Hemmelder, Marc H, Schouten, Marcel, Rodríguez-Ferrero, María Luisa, Crespo, Marta, Gansevoort, Ron T, and Hilbrands, Luuk B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Rare Diseases, Transplantation, Rehabilitation, Organ Transplantation, Kidney Disease, 7.1 Individual care needs, Management of diseases and conditions, Renal and urogenital, Good Health and Well Being, Adult, COVID-19, Humans, Intensive Care Units, Kidney Transplantation, Middle Aged, Outcome Assessment, Health Care, Retrospective Studies, SARS-CoV-2, Transplant Recipients, ERACODA Collaborators, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

BackgroundKidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19.MethodsWe analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021.ResultsWe included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status.ConclusionsIn kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.

Published
2022

9. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

Author

Bouwmans, Pim, Malahe, S.Reshwan K., Messchendorp, A. Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F., Gansevoort, Ron T., de Vries, Aiko P.J., Abrahams, Alferso C., Bemelman, Frederike J., Vervoort, Johanna P.M., Hilbrands, Luuk B., ten Dam, Marc A.G.J., van den Dorpel, René M.A., Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E.J., and Hemmelder, Marc H.

Published
2024
Full Text
View/download PDF

11. Acid ceramidase regulates innate immune memory

Author

Rother, Nils, Yanginlar, Cansu, Prévot, Geoffrey, Jonkman, Inge, Jacobs, Maaike, van Leent, Mandy M.T., van Heck, Julia, Matzaraki, Vasiliki, Azzun, Anthony, Morla-Folch, Judit, Ranzenigo, Anna, Wang, William, van der Meel, Roy, Fayad, Zahi A., Riksen, Niels P., Hilbrands, Luuk B., Lindeboom, Rik G.H., Martens, Joost H.A., Vermeulen, Michiel, Joosten, Leo A.B., Netea, Mihai G., Mulder, Willem J.M., van der Vlag, Johan, Teunissen, Abraham J.P., and Duivenvoorden, Raphaël

Published
2023
Full Text
View/download PDF

15. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients

Author

Abrahams, Alferso C., Baas, Marije C., Mattheussens, Wouter B., Philipsen, Ria H.L.A., Bouwmans, Pim, Hemmelder, Marc H., ten Dam, Marc A.G.J., Gommers, Lennert, Mourik, Djenolan van, Bogers, Susanne, van Dijk, Laura L.A., Standaar, Dorien, der Heiden, Marieke van, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Rots, Nynke, de Vries, Aiko P.J., Malahe, S. Reshwan K., Hartog, Yvette den, Rietdijk, Wim J.R., van Baarle, Debbie, de Kuiper, Ronella, Reijerkerk, Derek, Ras, Alicia M., Geers, Daryl, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B.M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M.L., de Vries, Rory D., Reinders, Marlies E.J., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

16. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study

Author

Imhof, C., Idzinga, C., Siegert, C., Baan, C.C., Konings, C.J.A.M., van Kessel, C., van Baarle, D., Diavatopoulos, D.A., Standaar, D., ten Hoope, E., Til, E., Remmerswaal, E.B.M., van der Klis, F., Fritsen, H.R., Stijnman, I., Brinkman, J.N., Cheng, J., den Biggelaar, L., ten Dam, M., Steenhuis, M., Zwerink, M., Braks, M.H.J., Willems, M., Kho, M.L., Rots, N., Vart, P., van der Molen, R.G., van den Dorpel, R.M.A., Malaha, R.S.R.K., ter Meulen, R.C.G., Rispens, T., Steenvoorden, T., de Ronde, T., Peters, V.J.P., Konijn, W.S., Janssen, W.M.T., Bos, W.J., Adema, Y.M.R., Vegting, Y., Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan-Stephan F., Bemelman, Frederike J., and Geerlings, Suzanne E.

Published
2023
Full Text
View/download PDF

17. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial

Author

Abrahams, Alferso C., Baas, Marije C., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, Standaar, Dorien, van der Heiden, Marieke, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Mattheussens, Wouter B., Philipsen, Ria H.L.A., van Mourik, Djenolan, Bogers, Susanne, van Dijk, Laura L.A., Rots, Nynke, Smits, Gaby, Kuijer, Marjan, Hemmelder, Marc H., Kho, Marcia M L, Messchendorp, A Lianne, Frölke, Sophie C, Imhof, Celine, Koomen, Vera JCH, Malahe, S Reshwan K, Vart, Priya, Geers, Daryl, de Vries, Rory D, GeurtsvanKessel, Corine H, Baan, Carla C, van der Molen, Renate G, Diavatopoulos, Dimitri A, Remmerswaal, Ester B M, van Baarle, Debbie, van Binnendijk, Rob, den Hartog, Gerco, de Vries, Aiko P J, Gansevoort, Ron T, Bemelman, Frederike J, Reinders, Marlies E J, Sanders, Jan-Stephan F, and Hilbrands, Luuk B

Published
2023
Full Text
View/download PDF

23. The effect of COVID-19 vaccination on kidney function and HLA antibody formation in patients with end-stage kidney disease and on kidney replacement treatment

Author

Imhof, Céline, primary, Messchendorp, A Lianne, additional, Bungener, Laura B, additional, Hepkema, Bouke G, additional, Kho, Marcia M L, additional, Reinders, Marlies E J, additional, Bemelman, Frederike J, additional, Hilbrands, Luuk B, additional, Gansevoort, Ron T, additional, and Sanders, Jan Stephan F, additional

Published
2024
Full Text
View/download PDF

26. Determination of the clinical relevance of donor epitope-specific HLA-antibodies in kidney transplantation

Author

CTI Otten, CDL Cluster Speciële Diagnostiek, Cancer, Infection & Immunity, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, CDL Unit SKIM, Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G, Wisse, Bram W, Reteig, Leon, Gruijters, Maartje L, Joosten, Irma, Allebes, Wil A, van der Meer, Arnold, Hilbrands, Luuk B, Baas, Marije C, Spierings, Eric, Hack, Cornelis E, van Reekum, Franka E, van Zuilen, Arjan D, Verhaar, Marianne C, Bots, Michiel L, Drop, Adriaan C A D, Plaisier, Loes, Melchers, Rowena C A, Seelen, Marc A J, Sanders, Jan Stephan, Hepkema, Bouke G, Lambeck, Annechien J A, Bungener, Laura B, Roozendaal, Caroline, Tilanus, Marcel G J, Voorter, Christina E, Wieten, Lotte, van Duijnhoven, Elly M, Gelens, Mariëlle A C J, Christiaans, Maarten H L, van Ittersum, Frans J, Nurmohamed, Shaikh A, Lardy, Neubury M, Swelsen, Wendy, van der Pant, Karlijn A M I, van der Weerd, Neelke C, Ten Berge, Ineke J M, Hoitsma, Andries, van der Boog, Paul J M, de Fijter, Johan W, Betjes, Michiel G H, Roelen, Dave L, Claas, Frans H, Bemelman, Frederike J, Senev, Aleksandar, Naesens, Maarten, Heidt, Sebastiaan, Otten, Henny G, CTI Otten, CDL Cluster Speciële Diagnostiek, Cancer, Infection & Immunity, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, CDL Unit SKIM, Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G, Wisse, Bram W, Reteig, Leon, Gruijters, Maartje L, Joosten, Irma, Allebes, Wil A, van der Meer, Arnold, Hilbrands, Luuk B, Baas, Marije C, Spierings, Eric, Hack, Cornelis E, van Reekum, Franka E, van Zuilen, Arjan D, Verhaar, Marianne C, Bots, Michiel L, Drop, Adriaan C A D, Plaisier, Loes, Melchers, Rowena C A, Seelen, Marc A J, Sanders, Jan Stephan, Hepkema, Bouke G, Lambeck, Annechien J A, Bungener, Laura B, Roozendaal, Caroline, Tilanus, Marcel G J, Voorter, Christina E, Wieten, Lotte, van Duijnhoven, Elly M, Gelens, Mariëlle A C J, Christiaans, Maarten H L, van Ittersum, Frans J, Nurmohamed, Shaikh A, Lardy, Neubury M, Swelsen, Wendy, van der Pant, Karlijn A M I, van der Weerd, Neelke C, Ten Berge, Ineke J M, Hoitsma, Andries, van der Boog, Paul J M, de Fijter, Johan W, Betjes, Michiel G H, Roelen, Dave L, Claas, Frans H, Bemelman, Frederike J, Senev, Aleksandar, Naesens, Maarten, Heidt, Sebastiaan, and Otten, Henny G

Published
2024

27. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients

Author

MS Nefrologie, Circulatory Health, Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., Gansevoort, Ron T., MS Nefrologie, Circulatory Health, Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., and Gansevoort, Ron T.

Published
2024

28. The effect of COVID-19 vaccination on kidney function and HLA antibody formation in patients with end-stage kidney disease and on kidney replacement treatment

Author

Imhof, Céline, Messchendorp, A. Lianne, Bungener, Laura B., Hepkema, Bouke G., Kho, Marcia M.L., Reinders, Marlies E.J., Bemelman, Frederike J., Hilbrands, Luuk B., Gansevoort, Ron T., Sanders, Jan Stephan F., Imhof, Céline, Messchendorp, A. Lianne, Bungener, Laura B., Hepkema, Bouke G., Kho, Marcia M.L., Reinders, Marlies E.J., Bemelman, Frederike J., Hilbrands, Luuk B., Gansevoort, Ron T., and Sanders, Jan Stephan F.

Published
2024

29. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

Author

MS Nefrologie, Circulatory Health, Bouwmans, Pim, Malahe, S. Reshwan K., Messchendorp, A. Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan Stephan F., Gansevoort, Ron T., de Vries, Aiko P.J., Abrahams, Alferso C., Bemelman, Frederike J., Vervoort, Johanna P.M., Hilbrands, Luuk B., ten Dam, Marc A.G.J., van den Dorpel, René M.A., Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E.J., Hemmelder, Marc H., RECOVAC Consortium, MS Nefrologie, Circulatory Health, Bouwmans, Pim, Malahe, S. Reshwan K., Messchendorp, A. Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan Stephan F., Gansevoort, Ron T., de Vries, Aiko P.J., Abrahams, Alferso C., Bemelman, Frederike J., Vervoort, Johanna P.M., Hilbrands, Luuk B., ten Dam, Marc A.G.J., van den Dorpel, René M.A., Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E.J., Hemmelder, Marc H., and RECOVAC Consortium

Published
2024

30. Ellipro scores of donor epitope specific HLA antibodies are not associated with kidney graft survival

Author

Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Kroesen, Bart Jan, Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Heidt, Sebastiaan, Otten, Henny G., Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Kroesen, Bart Jan, Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Heidt, Sebastiaan, and Otten, Henny G.

Abstract

In kidney transplantation, donor HLA antibodies are a risk factor for graft loss. Accessibility of donor eplets for HLA antibodies is predicted by the ElliPro score. The clinical usefulness of those scores in relation to transplant outcome is unknown. In a large Dutch kidney transplant cohort, Ellipro scores of pretransplant donor antibodies that can be assigned to known eplets (donor epitope specific HLA antibodies [DESAs]) were compared between early graft failure and long surviving deceased donor transplants. We did not observe a significant Ellipro score difference between the two cohorts, nor significant differences in graft survival between transplants with DESAs having high versus low total Ellipro scores. We conclude that Ellipro scores cannot be used to identify DESAs associated with early versus late kidney graft loss in deceased donor transplants.

Published
2024

31. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients

Author

Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., Gansevoort, Ron T., Messchendorp, A. Lianne, Sanders, Jan Stephan F., Abrahams, Alferso C., Bemelman, Frederike J., Bouwmans, Pim, van den Dorpel, René M.A., Hilbrands, Luuk B., Imhof, Céline, Reinders, Marlies E.J., Rispens, Theo, Steenhuis, Maurice, ten Dam, Marc A.G.J., Vart, Priya, de Vries, Aiko P.J., Hemmelder, Marc H., and Gansevoort, Ron T.

Abstract

Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i.e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54.7%) became seropositive (i.e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0.37 (0.19–0.47), p = 0.005). When studied on a continuous scale, we observed a log-linear relationship between antibody level and the risk for COVID-19 (HR 0.52 (0.31–0.89), p = 0.02). Similar results were found for COVID-19 severity. In conclusion, antibody level after COVID-19 vaccination is associated in a log-linear manner with the occurrence and severity of COVID-19 in KTRs. This implies that if future vaccinations are indicated, the aim should be to reach for as high an antibody level as possible and not only seropositivity to protect this vulnerable patient group from disease.

Published
2024

32. Determination of the clinical relevance of donor epitope-specific HLA-antibodies in kidney transplantation

Author

Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Reteig, Leon, Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Bots, Michiel L., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Lambeck, Annechien J.A., Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Senev, Aleksandar, Naesens, Maarten, Heidt, Sebastiaan, Otten, Henny G., Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Reteig, Leon, Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Bots, Michiel L., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Lambeck, Annechien J.A., Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Senev, Aleksandar, Naesens, Maarten, Heidt, Sebastiaan, and Otten, Henny G.

Abstract

In kidney transplantation, survival rates are still partly impaired due to the deleterious effects of donor specific HLA antibodies (DSA). However, not all luminex-defined DSA appear to be clinically relevant. Further analysis of DSA recognizing polymorphic amino acid configurations, called eplets or functional epitopes, might improve the discrimination between clinically relevant vs. irrelevant HLA antibodies. To evaluate which donor epitope-specific HLA antibodies (DESAs) are clinically important in kidney graft survival, relevant and irrelevant DESAs were discerned in a Dutch cohort of 4690 patients using Kaplan–Meier analysis and tested in a cox proportional hazard (CPH) model including nonimmunological variables. Pre-transplant DESAs were detected in 439 patients (9.4%). The presence of certain clinically relevant DESAs was significantly associated with increased risk on graft loss in deceased donor transplantations (p < 0.0001). The antibodies recognized six epitopes of HLA Class I, 3 of HLA-DR, and 1 of HLA-DQ, and most antibodies were directed to HLA-B (47%). Fifty-three patients (69.7%) had DESA against one donor epitope (range 1–5). Long-term graft survival rate in patients with clinically relevant DESA was 32%, rendering DESA a superior parameter to classical DSA (60%). In the CPH model, the hazard ratio (95% CI) of clinically relevant DESAs was 2.45 (1.84–3.25) in deceased donation, and 2.22 (1.25–3.95) in living donation. In conclusion, the developed model shows the deleterious effect of clinically relevant DESAs on graft outcome which outperformed traditional DSA-based risk analysis on antigen level.

Published
2024

33. Primary Exposure to SARS-CoV-2 via Infection or Vaccination Determines Mucosal Antibody-Dependent ACE2 Binding Inhibition

Author

Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., Diavatopoulos, Dimitri A., Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., and Diavatopoulos, Dimitri A.

Abstract

Background: Mucosal antibodies play a critical role in preventing SARS-CoV-2 infections or reinfections by blocking the interaction of the receptor-binding domain (RBD) with the angiotensin-converting enzyme 2 (ACE2) receptor on the cell surface. In this study, we investigated the difference between the mucosal antibody response after primary infection and vaccination. Methods: We assessed longitudinal changes in the quantity and capacity of nasal antibodies to neutralize the interaction of RBD with the ACE2 receptor using the spike protein and RBD from ancestral SARS-CoV-2 (Wuhan-Hu-1), as well as the RBD from the Delta and Omicron variants. Results: Significantly higher mucosal IgA concentrations were detected postinfection vs postvaccination, while vaccination induced higher IgG concentrations. However, ACE2-inhibiting activity did not differ between the cohorts. Regarding whether IgA or IgG drove ACE2 inhibition, infection-induced binding inhibition was driven by both isotypes, while postvaccination binding inhibition was mainly driven by IgG. Conclusions: Our study provides new insights into the relationship between antibody isotypes and neutralization by using a sensitive and high-Throughput ACE2 binding inhibition assay. Key differences are highlighted between vaccination and infection at the mucosal level, showing that despite differences in the response quantity, postinfection and postvaccination ACE2 binding inhibition capacity did not differ.

Published
2024

34. Ellipro scores of donor epitope specific HLA antibodies are not associated with kidney graft survival

Author

CTI Otten, CTI, CDL Cluster Speciële Diagnostiek, Cancer, Infection & Immunity, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, CDL Unit SKIM, CTI CFF, Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Kroesen, Bart Jan, Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Heidt, Sebastiaan, Otten, Henny G., CTI Otten, CTI, CDL Cluster Speciële Diagnostiek, Cancer, Infection & Immunity, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, CDL Unit SKIM, CTI CFF, Kardol-Hoefnagel, Tineke, Senejohnny, Danial Mohammadi, Kamburova, Elena G., Wisse, Bram W., Gruijters, Maartje L., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Kroesen, Bart Jan, Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., Heidt, Sebastiaan, and Otten, Henny G.

Published
2024

35. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease:A nested case-control study

Author

Bouwmans, Pim, Malahe, S Reshwan K, Messchendorp, A Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F, Gansevoort, Ron T, de Vries, Aiko P J, Abrahams, Alferso C, Bemelman, Frederike J, Vervoort, Johanna P M, Hilbrands, Luuk B, Ten Dam, Marc A G J, van den Dorpel, René M A, Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E J, Hemmelder, Marc H, Bouwmans, Pim, Malahe, S Reshwan K, Messchendorp, A Lianne, Vart, Priya, Imhof, Céline, Sanders, Jan-Stephan F, Gansevoort, Ron T, de Vries, Aiko P J, Abrahams, Alferso C, Bemelman, Frederike J, Vervoort, Johanna P M, Hilbrands, Luuk B, Ten Dam, Marc A G J, van den Dorpel, René M A, Rispens, Theo, Steenhuis, Maurice, Reinders, Marlies E J, and Hemmelder, Marc H

Abstract

Background: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease. Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4–G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition. Results: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17–1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70–0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61–8.25], P = 0.003). Conclusions: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.

Published
2024

36. SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Author

Imhof, Céline, Messchendorp, A. Lianne, van der Heiden, Marieke, Baan, Carla C., van der Molen, Renate G., Remmerswaal, Ester B. M., de Vries, Rory D., Diavatopoulos, Dimitri A., Boerma, Annemarie, Bakker, Femke J., Oosterhout, Emily, Bemelman, Frederike J., Hilbrands, Luuk B., Reinders, Marlies E. J., Gansevoort, Ron T., Sanders, Jan-Stephan, and van Baarle, Debbie

Published
2022
Full Text
View/download PDF

38. Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons

Author

Rother, Nils, Yanginlar, Cansu, Lindeboom, Rik G.H., Bekkering, Siroon, van Leent, Mandy M.T., Buijsers, Baranca, Jonkman, Inge, de Graaf, Mark, Baltissen, Marijke, Lamers, Lieke A., Riksen, Niels P., Fayad, Zahi A., Mulder, Willem J.M., Hilbrands, Luuk B., Joosten, Leo A.B., Netea, Mihai G., Vermeulen, Michiel, van der Vlag, Johan, and Duivenvoorden, Raphaël

Published
2020
Full Text
View/download PDF

40. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.

Author

Ergün, Mehmet, Jansen, Anouk M E, Hilbrands, Luuk B, Kort, Elizabeth de, Kunst, Henricus, Reijers, Monique H E, Schouten, Jeroen A, Verweij, Paul E, and Brüggemann, Roger J M

Subjects
DRUG monitoring, MYCOSES, ASPERGILLOSIS, TRIAZOLES, SCIENTIFIC observation
Abstract

Background Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This retrospective observational study aimed to describe the usage of isavuconazole in clinical practice with an in-depth evaluation of individual isavuconazole exposure. Methods Patients treated with isavuconazole were evaluated based on retrospective data, including therapeutic drug monitoring (TDM) data and efficacy and safety data. Additionally, we calculated the individual isavuconazole exposure described by the average AUC24 over the first 7 days of treatment by means of non-linear mixed-effects modelling and compared this with the currently desired lower target AUC of 60 mg·h/L. Results Ninety-nine patients treated with isavuconazole were evaluated. In our real-life cohort, isavuconazole was often deployed off-label in patients with non-classical host factors and infections with non- Aspergillus and non-Mucorales species. Isavuconazole was most often chosen for its safety profile, even after prior triazole treatment with manifestations of toxicity. TDM and subsequent dosage adjustments were frequently performed. The individual average AUC24 over 7 days was above 60 mg·h/L in 29 out of 77 (37.7%) patients. Conclusions This overview provides practical insights that can aid clinicians in the management of their patients with IFD. Our study shows that isavuconazole was used in a diverse patient population and was well tolerated overall. Individual isavuconazole exposure reflected by the average AUC24 over the first 7 days of treatment was generally low and variable. Dosage adjustments following TDM were frequently performed. Our experience shows that isavuconazole is a feasible alternative after prior azole treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Determination of the clinical relevance of donor epitope‐specific HLA‐antibodies in kidney transplantation

Author

Kardol‐Hoefnagel, Tineke, primary, Senejohnny, Danial Mohammadi, additional, Kamburova, Elena G., additional, Wisse, Bram W., additional, Reteig, Leon, additional, Gruijters, Maartje L., additional, Joosten, Irma, additional, Allebes, Wil A., additional, van der Meer, Arnold, additional, Hilbrands, Luuk B., additional, Baas, Marije C., additional, Spierings, Eric, additional, Hack, Cornelis E., additional, van Reekum, Franka E., additional, van Zuilen, Arjan D., additional, Verhaar, Marianne C., additional, Bots, Michiel L., additional, Drop, Adriaan C. A. D., additional, Plaisier, Loes, additional, Melchers, Rowena C. A., additional, Seelen, Marc A. J., additional, Sanders, Jan Stephan, additional, Hepkema, Bouke G., additional, Lambeck, Annechien J. A., additional, Bungener, Laura B., additional, Roozendaal, Caroline, additional, Tilanus, Marcel G. J., additional, Voorter, Christina E., additional, Wieten, Lotte, additional, van Duijnhoven, Elly M., additional, Gelens, Mariëlle A. C. J., additional, Christiaans, Maarten H. L., additional, van Ittersum, Frans J., additional, Nurmohamed, Shaikh A., additional, Lardy, Neubury M., additional, Swelsen, Wendy, additional, van der Pant, Karlijn A. M. I., additional, van der Weerd, Neelke C., additional, ten Berge, Ineke J. M., additional, Hoitsma, Andries, additional, van der Boog, Paul J. M., additional, de Fijter, Johan W., additional, Betjes, Michiel G. H., additional, Roelen, Dave L., additional, Claas, Frans H., additional, Bemelman, Frederike J., additional, Senev, Aleksandar, additional, Naesens, Maarten, additional, Heidt, Sebastiaan, additional, and Otten, Henny G., additional

Published
2024
Full Text
View/download PDF

42. Antibodies against ARHGDIB are associated with long-term kidney graft loss

Author

Kamburova, Elena G., Gruijters, Maartje L., Kardol-Hoefnagel, Tineke, Wisse, Bram W., Joosten, Irma, Allebes, Wil A., van der Meer, Arnold, Hilbrands, Luuk B., Baas, Marije C., Spierings, Eric, Hack, Cornelis E., van Reekum, Franka E., van Zuilen, Arjan D., Verhaar, Marianne C., Bots, Michiel L., Drop, Adriaan C.A.D., Plaisier, Loes, Melchers, Rowena C.A., Seelen, Marc A.J., Sanders, Jan Stephan, Hepkema, Bouke G., Lambeck, Annechien J.A., Bungener, Laura B., Roozendaal, Caroline, Tilanus, Marcel G.J., Voorter, Christina E., Wieten, Lotte, van Duijnhoven, Elly M., Gelens, Mariëlle A.C.J., Christiaans, Maarten H.L., van Ittersum, Frans J., Nurmohamed, Shaikh A., Lardy, Neubury M., Swelsen, Wendy, van der Pant, Karlijn A.M.I., van der Weerd, Neelke C., ten Berge, Ineke J.M., Hoitsma, Andries, van der Boog, Paul J.M., de Fijter, Johan W., Betjes, Michiel G.H., Heidt, Sebastiaan, Roelen, Dave L., Claas, Frans H., Bemelman, Frederike J., and Otten, Henny G.

Published
2019
Full Text
View/download PDF

43. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Author

Sanders, Jan-Stephan F., Bemelman, Frederike J., Messchendorp, A. Lianne, Baan, Carla C., van Baarle, Debbie, van Binnendijk, Rob, Diavatopoulos, Dimitri A., Frölke, Sophie C., Geers, Daryl, GeurtsvanKessel, Corine H., den Hartog, Gerco, van der Heiden, Marieke, Imhof, Celine, Kho, Marcia M. L., Koopmans, Marion P. G., Malahe, S. Reshwan K., Mattheussens, Wouter B., van der Molen, Renate, van Mourik, Djenolan, Remmerswaal, Ester B. M., Rots, Nynke, Vart, Priya, de Vries, Rory D., Gansevoort, Ron T., Hilbrands, Luuk B., and Reinders, Marlies E. J.

Published
2021
Full Text
View/download PDF

45. Primary Exposure to SARS-CoV-2 via Infection or Vaccination Determines Mucosal Antibody-Dependent ACE2 Binding Inhibition

Author

Fröberg, Janeri, primary, Koomen, Vera J C H, additional, van der Gaast-de Jongh, Christa E, additional, Philipsen, Ria, additional, GeurtsvanKessel, Corine H, additional, de Vries, Rory D, additional, Baas, Marije C, additional, van der Molen, Renate G, additional, de Jonge, Marien I, additional, Hilbrands, Luuk B, additional, Huynen, Martijn A, additional, and Diavatopoulos, Dimitri A, additional

Published
2023
Full Text
View/download PDF

47. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients

Author

Malahe, S. Reshwan K., primary, Hartog, Yvette den, additional, Rietdijk, Wim J.R., additional, van Baarle, Debbie, additional, de Kuiper, Ronella, additional, Reijerkerk, Derek, additional, Ras, Alicia M., additional, Geers, Daryl, additional, Diavatopoulos, Dimitri A., additional, Messchendorp, A. Lianne, additional, van der Molen, Renate G., additional, Remmerswaal, Ester B.M., additional, Bemelman, Frederike J., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Sanders, Jan-Stephan, additional, GeurtsvanKessel, Corine H., additional, Kho, Marcia M.L., additional, de Vries, Rory D., additional, Reinders, Marlies E.J., additional, Baan, Carla C., additional, Abrahams, Alferso C., additional, Baas, Marije C., additional, Mattheussens, Wouter B., additional, Philipsen, Ria H.L.A., additional, Bouwmans, Pim, additional, Hemmelder, Marc H., additional, ten Dam, Marc A.G.J., additional, Gommers, Lennert, additional, Mourik, Djenolan van, additional, Bogers, Susanne, additional, van Dijk, Laura L.A., additional, Standaar, Dorien, additional, der Heiden, Marieke van, additional, Adema, Yvonne M.R., additional, Boer-Verschragen, Marieken J., additional, Rots, Nynke, additional, and de Vries, Aiko P.J., additional

Published
2023
Full Text
View/download PDF

48. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future

Author

Noordzij, Marlies, Meijers, Björn, Gansevoort, Ron T, Covic, Adrian, Duivenvoorden, Raphaël, Hilbrands, Luuk B, Hemmelder, Marc H, Jager, Kitty J, Mjoen, Geir, Nistor, Ionut, Parshina, Ekaterina, Pessolano, Giuseppina, Tuglular, Serhan, Vart, Priya, Zanoli, Luca, Franssen, Casper F M, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and Noordzij M., Meijers B., Gansevoort R. T., Covic A., Duivenvoorden R., Hilbrands L. B., Hemmelder M. H., Jager K. J., Mjoen G., Nistor I., et al.

Subjects
Internal Diseases, Urology, Sağlık Bilimleri, İç Hastalıkları, Clinical Medicine (MED), All institutes and research themes of the Radboud University Medical Center, UROLOGY & NEPHROLOGY, Health Sciences, Klinik Tıp (MED), KIDNEY-TRANSPLANT, guidelines, ÜROLOJİ VE NEFROLOJİ, Transplantation, Internal Medicine Sciences, Science & Technology, hemodialysis, Klinik Tıp, SARS-CoV-2, MORTALITY, Dahili Tıp Bilimleri, centre practices, CLINICAL MEDICINE, Urology & Nephrology, virus transmission, Tıp, DIALYSIS PATIENTS, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nefroloji, Nephrology, ERACODA, Üroloji, Medicine, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Life Sciences & Biomedicine
Abstract

Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave. Methods We analyzed IPC measures taken by hemodialysis centres treating patients presenting with COVID-19 between 1 March 2020 and 31 July 2020 and that completed the European Renal Association COVID-19 Database centre questionnaire. Additionally, we made an inventory of guidelines published in European countries to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dialysis centres. Results Data from 73 dialysis units located in and bordering Europe were analyzed. All participating centres implemented IPC measures to mitigate the impact of SARS-CoV-2 during the first pandemic wave. Measures mentioned most often included triage with questions before entering the dialysis ward, measuring body temperature, hand disinfection, masking for all patients and staff, and personal protective equipment for staff members. These measures were also recommended in most of the 14 guidelines that were identified in the inventory of national guidelines and were also scored as being among the most important measures by the authors of this paper. Heterogeneity existed between centres and national guidelines regarding the minimal distance between dialysis chairs and recommendations regarding isolation and cohorting. Conclusions Although variation existed, measures to prevent transmission of SARS-CoV-2 were relatively similar across centres and national guidelines. Further research is needed to assess causal relationships between measures taken and spread of SARS-CoV-2.

Published
2022
Full Text
View/download PDF

50. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study

Author

Frölke, Sophie C., primary, Bouwmans, Pim, additional, Messchendorp, A. Lianne, additional, Vervoort, Johanna P.M., additional, Abrahams, Alferso C., additional, de Vries, Aiko P.J., additional, Nieuwkerk, Pythia T., additional, Hemmelder, Marc H., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Reinders, Marlies E.J., additional, Sanders, Jan-Stephan F., additional, Bemelman, Frederike J., additional, Geerlings, Suzanne E., additional, Imhof, C., additional, Idzinga, C., additional, Siegert, C., additional, Baan, C.C., additional, Konings, C.J.A.M., additional, van Kessel, C., additional, van Baarle, D., additional, Diavatopoulos, D.A., additional, Standaar, D., additional, ten Hoope, E., additional, Til, E., additional, Remmerswaal, E.B.M., additional, van der Klis, F., additional, Fritsen, H.R., additional, Stijnman, I., additional, Brinkman, J.N., additional, Cheng, J., additional, den Biggelaar, L., additional, ten Dam, M., additional, Steenhuis, M., additional, Zwerink, M., additional, Braks, M.H.J., additional, Willems, M., additional, Kho, M.L., additional, Rots, N., additional, Vart, P., additional, van der Molen, R.G., additional, van den Dorpel, R.M.A., additional, Malaha, R.S.R.K., additional, ter Meulen, R.C.G., additional, Rispens, T., additional, Steenvoorden, T., additional, de Ronde, T., additional, Peters, V.J.P., additional, Konijn, W.S., additional, Janssen, W.M.T., additional, Bos, W.J., additional, Adema, Y.M.R., additional, and Vegting, Y., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results